Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple cooking tweak reverse fatty liver? a new trial puts low-AGE foods to the test.

NCT ID NCT07723196

Disease control Sponsor: Universidad de Guanajuato Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This trial tests whether a diet low in advanced glycation end products (AGEs)—compounds formed when food is grilled, fried, or toasted—can improve liver function and reduce fat buildup in adults with metabolic fatty liver disease. Over 12 weeks, one group will follow AGE-restricted cooking methods while the other eats normally. Researchers will measure liver enzymes, fat levels via ultrasound, and blood markers to see if this dietary shift makes a difference.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a diet low in advanced glycation end products (AGEs), achieved by changing food preparation methods (e.g., avoiding grilling, frying, toasting)
What this could lead to
If it works, this could point toward a simple dietary approach to improve liver health and reduce fat buildup in people with fatty liver disease.
What could go wrong
This is a small, early trial with only 48 participants. The diet change is modest—only altering cooking methods—so the effect may be small or hard to detect. Results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 48 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Men and women between 18 and 55 years old. 2. High consumption of essential fatty acids (EFAs) \> 8000 KU. 3. With metabolic hepatic steatosis (MetHS) of any degree. 4. Not currently undergoing nutritional treatment. 5. Sedentary lifestyle. 6. Denies alcoholism. 7. Not taking any medications. 8. No other health conditions. Exclusion Criteria: 1. Men and women undergoing treatment for metabolic diseases. 2. Men and women with cardiovascular and/or coronary diseases. 3. Pregnant women. 4. Men and women undergoing hormone therapy. 5. Men and women taking dietary supplements. 6. Men and women who refuse to sign the informed consent form. 7. In cases where space-occupying masses (tumors) are detected during the ultrasound.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Masld (metabolic dysfunction-associated steatotic liver disease) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Masld (metabolic dysfunction-associated steatotic liver disease)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Universidad de Guanajuato

    Celaya, Guanajuato, 38140, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.